6 Works
Additional file 1 of EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
Jonas Leichsenring, Valentina Vladimirova, Christine Solbach, Thomas Karn, Beyhan Ataseven, Bruno Valentin Sinn, Jana Barinoff, Volkmar Müller, Jens-Uwe Blohmer, Christian Schem, Knut Engels, Frederik Marmé, Annette Fisseler-Eckhoff, Peter A. Fasching, Elmar Stickeler, Marion van Mackelenbergh, Carsten Denkert, Albrecht Stenzinger, Sibylle Loibl & Stefan Gröschel
Additional file 1: Supplementary Figure 1. Flow diagram of patients included in the analysis set from GeparTrio study.
Additional file 1 of EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
Jonas Leichsenring, Valentina Vladimirova, Christine Solbach, Thomas Karn, Beyhan Ataseven, Bruno Valentin Sinn, Jana Barinoff, Volkmar Müller, Jens-Uwe Blohmer, Christian Schem, Knut Engels, Frederik Marmé, Annette Fisseler-Eckhoff, Peter A. Fasching, Elmar Stickeler, Marion van Mackelenbergh, Carsten Denkert, Albrecht Stenzinger, Sibylle Loibl & Stefan Gröschel
Additional file 1: Supplementary Figure 1. Flow diagram of patients included in the analysis set from GeparTrio study.
Additional file 2 of EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
Jonas Leichsenring, Valentina Vladimirova, Christine Solbach, Thomas Karn, Beyhan Ataseven, Bruno Valentin Sinn, Jana Barinoff, Volkmar Müller, Jens-Uwe Blohmer, Christian Schem, Knut Engels, Frederik Marmé, Annette Fisseler-Eckhoff, Peter A. Fasching, Elmar Stickeler, Marion van Mackelenbergh, Carsten Denkert, Albrecht Stenzinger, Sibylle Loibl & Stefan Gröschel
Additional file 2: Supplementary Figure 2. Distribution of EVI1 continuous expression in breast cancer: A: Histogram of EVI1 continuous expression in the entire cohort (N=993); B: Boxplots of EVI1 continuous expression within breast cancer subtypes. Note, 882/993 patients with available BC subtype information were included in this analysis. Horizontal bold lines present EVI1 median values of 116.65 in HR+/HER2-, 98.67 in HR+/HER2+, 114.77in HR-/HER2+, and 115.64 in TNBC; boxes present the interquartile range between first...
Additional file 3 of EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
Jonas Leichsenring, Valentina Vladimirova, Christine Solbach, Thomas Karn, Beyhan Ataseven, Bruno Valentin Sinn, Jana Barinoff, Volkmar Müller, Jens-Uwe Blohmer, Christian Schem, Knut Engels, Frederik Marmé, Annette Fisseler-Eckhoff, Peter A. Fasching, Elmar Stickeler, Marion van Mackelenbergh, Carsten Denkert, Albrecht Stenzinger, Sibylle Loibl & Stefan Gröschel
Additional file 3: Supplementary Figure 3. Kaplan-Meier estimates of DFS (A) and OS (B) according to EVI1 expression in the non-pCR subgroup. Abbreviations:pCR, pathological complete response; DFS, disease-free survival; OS, overallsurvival.
Additional file 2 of EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
Jonas Leichsenring, Valentina Vladimirova, Christine Solbach, Thomas Karn, Beyhan Ataseven, Bruno Valentin Sinn, Jana Barinoff, Volkmar Müller, Jens-Uwe Blohmer, Christian Schem, Knut Engels, Frederik Marmé, Annette Fisseler-Eckhoff, Peter A. Fasching, Elmar Stickeler, Marion van Mackelenbergh, Carsten Denkert, Albrecht Stenzinger, Sibylle Loibl & Stefan Gröschel
Additional file 2: Supplementary Figure 2. Distribution of EVI1 continuous expression in breast cancer: A: Histogram of EVI1 continuous expression in the entire cohort (N=993); B: Boxplots of EVI1 continuous expression within breast cancer subtypes. Note, 882/993 patients with available BC subtype information were included in this analysis. Horizontal bold lines present EVI1 median values of 116.65 in HR+/HER2-, 98.67 in HR+/HER2+, 114.77in HR-/HER2+, and 115.64 in TNBC; boxes present the interquartile range between first...
Additional file 3 of EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
Jonas Leichsenring, Valentina Vladimirova, Christine Solbach, Thomas Karn, Beyhan Ataseven, Bruno Valentin Sinn, Jana Barinoff, Volkmar Müller, Jens-Uwe Blohmer, Christian Schem, Knut Engels, Frederik Marmé, Annette Fisseler-Eckhoff, Peter A. Fasching, Elmar Stickeler, Marion van Mackelenbergh, Carsten Denkert, Albrecht Stenzinger, Sibylle Loibl & Stefan Gröschel
Additional file 3: Supplementary Figure 3. Kaplan-Meier estimates of DFS (A) and OS (B) according to EVI1 expression in the non-pCR subgroup. Abbreviations:pCR, pathological complete response; DFS, disease-free survival; OS, overallsurvival.
Affiliations
-
Charité - University Medicine Berlin6
-
Universitätsklinikum Erlangen6
-
University Hospital Heidelberg6
-
Sankt Gertrauden Krankenhaus6
-
Philipps University of Marburg6
-
University Hospital Schleswig-Holstein6
-
University Medical Center Hamburg-Eppendorf6
-
Universitätsklinikum Aachen6
-
LMU Klinikum6
-
Universitätsklinikum Gießen und Marburg6